Literature DB >> 32961546

The newborn infant parasympathetic evaluation index for acute procedural pain assessment in preterm infants.

Julie Gendras1,2, Pauline Lavenant1,2, Iona Sicard-Cras1,2, Maëlys Consigny3, Laurent Misery2, Kanwaljeet J S Anand4, Jacques Sizun1,2, Jean-Michel Roué5,6,7.   

Abstract

BACKGROUND: Accurate assessments of pain in hospitalized preterm infants present a major challenge in improving the short- and long-term consequences associated with painful experiences. We evaluated the ability of the newborn infant parasympathetic evaluation (NIPE) index to detect acute procedural pain in preterm infants.
METHODS: Different painful and stressful interventions were prospectively observed in preterm infants born at 25 + 0 to 35 + 6 weeks gestation. Pain responses were measured using the composite Premature Infant Pain Profile Revised (PIPP-R) scale, the NIPE index, and skin conductance responses (SCR). Outcome measures were correlations between the NIPE index, the PIPP-R score, and the SCR. Sensitivity/specificity analyses tested the accuracy of the NIPE index and SCR.
RESULTS: Two hundred and fifty-four procedures were recorded in 90 preterm infants. No significant correlation was found between PIPP-R and the NIPE index. PIPP-R and SCR were positively correlated (r = 0.27, P < 0.001), with stronger correlations for painful procedures (r = 0.68, P < 0.001) and especially for skin-breaking procedures (r = 0.82, P < 0.001). The NIPE index and SCR had high sensitivity and high negative predictive values to predict PIPP-R > 10, especially for skin-breaking painful procedures.
CONCLUSIONS: We found no significant correlation between the NIPE index and PIPP-R during routine painful or stressful procedures in preterm infants. IMPACT: Exposure to repetitive pain can lead to neurodevelopmental sequelae. Behavior-based pain scales have limited clinical utility, especially for preterm infants. New devices for monitoring physiological responses to pain have not been validated sufficiently in preterm infants. This study found that the NIPE index was not significantly correlated to the validated PIPP-R scale during acute procedural pain. Secondary analysis of this study showed that NIPE index and SCRs may help to exclude severe pain in preterm infants. In clinical practice, measurements of physiological parameters should be combined with behavior-based scales for multidimensional pain assessments.

Entities:  

Mesh:

Year:  2020        PMID: 32961546     DOI: 10.1038/s41390-020-01152-4

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  2 in total

1.  Newborn infant parasympathetic evaluation (NIPE) as a predictor of hemodynamic response in children younger than 2 years under general anesthesia: an observational pilot study.

Authors:  Kan Zhang; Siyuan Wang; Lei Wu; Yun'an Song; Meihua Cai; Mazhong Zhang; Jijian Zheng
Journal:  BMC Anesthesiol       Date:  2019-06-11       Impact factor: 2.217

2.  How well do clinical pain assessment tools reflect pain in infants?

Authors:  Rebeccah Slater; Anne Cantarella; Linda Franck; Judith Meek; Maria Fitzgerald
Journal:  PLoS Med       Date:  2008-06-24       Impact factor: 11.069

  2 in total
  2 in total

1.  Procedural Pain Assessment in Infants Without Analgosedation: Comparison of Newborn Infant Parasympathetic Evaluation and Skin Conductance Activity - A Pilot Study.

Authors:  Wojciech Walas; Zenon P Halaba; Tomasz Szczapa; Julita Latka-Grot; Iwona Maroszyńska; Ewelina Malinowska; Magdalena Rutkowska; Agata Kubiaczyk; Monika Wrońska; Michał Skrzypek; Julien De Jonckheere; Mickael Jean-Noel; Andrzej Piotrowski
Journal:  Front Pediatr       Date:  2022-01-11       Impact factor: 3.418

2.  Usefulness of two types of pain monitors in newborns treated in NICU, in the opinion of experts: Results of the survey.

Authors:  Wojciech Walas; Julita Latka-Grot; Tomasz Szczapa; Iwona Maroszyńska; Magdalena Rutkowska; Alicja Bartkowska-Śniatkowska; Andrzej Piotrowski
Journal:  J Mother Child       Date:  2022-04-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.